131
Participants
Start Date
September 17, 2021
Primary Completion Date
June 29, 2023
Study Completion Date
June 29, 2023
Eptinezumab
Eptinezumab will be administered per schedule specified in the arm description.
Rigshospitalet Glostrup, Glostrup Municipality
Hospitalsenhed Midt og Regionshospitalet Viborg, Viborg
Charité Campus Mitte, Berlin
Ospedale Molinette - Clinica Neurologica II - Centro Cefalee, Turin
Hôpital de la Timone, Marseille
Dent Neurologic Institute - Amherst, Amherst
Thomas Jefferson University Hospital - Center City Campus, Philadelphia
Terveystalo Turku Pulssi, Turku
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Fondazione Istituto Neurologico Car..., Milan
Fondazione Mondino - Istituto Neurologico Nazionale a Carattere Scientifico IRCCS, Pavia
Hospital Universitario Marques de Valdecilla, Santander
IRCCS Istituto Delle Scienze Neurologiche di Bologna, Bologna
Hospital Universitario Virgen del Rocío, Seville
Centre Hospitalier Universitaire de Saint-Étienne, Saint-Priest-en-Jarez
Cleveland Clinic - Neurological Institute, Cleveland
Hospital Clínico Universitario de Valencia, Valencia
Hospital Clínico Universitario de Valladolid, Valladolid
Hôpital Roger Salengro, Lille
Kopfschmerzzentrum Frankfurt, Frankfurt am Main
Hôpital Pierre Wertheimer, Bron
Hôpital Lariboisière, Paris
New England Institute for Neurology and Headache, Stamford
Michigan Headache and Neurological Institute, Ann Arbor
Terveystalo Ruoholahti, Helsinki
Hôpital Cimiez, Nice
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - San Raffaele Pisana, Rome
Canisius-Wilhelmina Ziekenhuis, Nijmegen
Brain Research Center - Amsterdam, Amsterdam
Hospital Universitari Vall d'Hebron, Barcelona
The Walton Centre NHS Foundation Trust, Liverpool
King's College Hospital NHS Foundation Trust, London
H. Lundbeck A/S
INDUSTRY